Quality of life is impaired similarly in heart failure patients with preserved and reduced ejection fraction by Hoekstra, Tialda et al.
  
 University of Groningen
Quality of life is impaired similarly in heart failure patients with preserved and reduced ejection
fraction
Hoekstra, Tialda; Lesman-Leegte, Ivonne; van Veldhuisen, Dirk J.; Sanderman, Robbert;
Jaarsma, Tiny
Published in:
European Journal of Heart Failure
DOI:
10.1093/eurjhf/hfr072
IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date:
2011
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
Hoekstra, T., Lesman-Leegte, I., van Veldhuisen, D. J., Sanderman, R., & Jaarsma, T. (2011). Quality of
life is impaired similarly in heart failure patients with preserved and reduced ejection fraction. European
Journal of Heart Failure, 13(9), 1013-1018. https://doi.org/10.1093/eurjhf/hfr072
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the
author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the
number of authors shown on this cover page is limited to 10 maximum.
Download date: 12-11-2019
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Quality of life is impaired similarly in heart
failure patients with preserved and reduced
ejection fraction†
Tialda Hoekstra1*, Ivonne Lesman-Leegte1, Dirk J. van Veldhuisen1,
Robbert Sanderman2, and Tiny Jaarsma1,3
1Department of Cardiology, University Medical Center Groningen, University of Groningen, PO Box 30.001, 9700 RB Groningen, The Netherlands; 2Department of Health Sciences,
University Medical Center Groningen, University of Groningen, Health Psychology Section, The Netherlands; and 3Department of Social – and Welfare Studies, Linko¨pings
Universiteit, Norrko¨ping, Sweden
Received 7 February 2011; revised 12 April 2011; accepted 27 April 2011
Aims To compare quality of life (QoL) in heart failure (HF) patients with preserved ejection fraction (HF-PEF) and HF
patients with reduced ejection fraction (HF-REF) in a well-defined HF population.
Methods
and results
Patients with HF-PEF [left ventricular ejection fraction (LVEF) ≥40%] were matched by age and gender to patients
with HF-REF (LVEF ,40%). In the current study, we only included HF patients with a B-type natriuretic peptide level
(BNP) .100 pg/mL. Quality of life was assessed by Cantril’s Ladder of Life, RAND-36, and the Minnesota Living with
Heart Failure questionnaire, and impairment of QoL was adjusted for by BNP as a marker for severity of HF. We
examined a total of 290 HF patients, of whom 145 had HF-PEF (41% female; age 72+10; LVEF 51+8%) and
145 had HF-REF (41% female; age 73+ 10, LVEF 26+7%). All HF patients reported markedly low scores of
QoL, both on the general and disease-specific QoL questionnaires. Quality of life between patients with HF-PEF
and HF-REF did not differ significantly. When adjusting the QoL scores for BNP, an association between QoL and
LVEF was not found, i.e. patients with HF-PEF and HF-REF with similar BNP levels had the same impairment in QoL.
Conclusion Quality of life is similarly impaired in patients with HF-PEF as in HF-REF. These findings further support the need for
more pharmacological and non-pharmacological studies in patients with HF-PEF.
Trial registration number: NCT 98675639.
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Introduction
Heart failure (HF) has a major impact on the quality of life (QoL) of
patients, in physical, mental, and social domains.1,2 Patients with HF
have a significantly lower QoL than an age- and gender-matched
members of the community.3 But even compared with other
chronically ill patients, patients with HF have similar or even
more impaired physical and mental health.4 In recent years,
patient-centred outcomes, such as QoL, have gained greater
importance, particularly because life expectancies for HF patients
have increased, and HF patients have to adjust to living with a
chronic condition and for many (elderly) patients QoL appears
to be more important than longer survival.5,6 In addition, impaired
QoL is increasingly associated with a poor outcome in HF.7,8
In HF patients, the large majority of studies have been conducted
in patients with a reduced ejection fraction (HF-REF). However, at
least 50% of all HF patients have HF with a preserved ejection frac-
tion (HF-PEF).9,10 Symptoms and signs often seem similar in patients
with HF-PEF and HF-REF.11 However, no treatment has been shown
to be effective in HF-PEF patients, and current guidelines do not
support the use of any class of drugs in this patient category.1
There is only limited knowledge about the QoL of patients with
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HF-PEF compared with patients with HF-REF. Five studies that com-
pared QoL in these two populations showed inconsistent results,
reporting either no significant differences in QoL11–14 or more
impaired QoL in patients with HF-REF.15.
Previous reports about the QoL of patients with HF-PEF were
not only relatively small, but they also used the New York Heart
Association (NYHA) functional class to adjust for severity of HF,
which of course affects QoL as well. Indeed, none of the afore-
mentioned studies used an objective diagnostic marker for the
severity (and presence) of HF. Especially in patients with
HF-PEF, the diagnosis of HF is often more difficult, and in fact
some patients with assumed HF-PEF do not have HF but suffer
from other conditions such as anaemia, lung disease, or even
depression.9,10.
We therefore studied a large number of QoL measurements in a
group of patients with HF-PEF, compared with a matched group of
patients with HF-REF. In order to try to obtain an objective par-
ameter for the severity of HF, we used plasma levels of B-type
natriuretic peptide (BNP), since this is an independent and reliable
marker of HF severity.16.
Methods
Patient population
Data from patients participating in the COACH (Coordinating study
evaluating Advising and Counselling in Heart failure) study were
used. COACH was a multicentre, randomized clinical trial on the
effect of a disease management programme in HF, the design and
main results have been published.17,18 In short, 1023 patients from
17 hospitals in the Netherlands were enrolled in the COACH study.
Patients were included in the study at the end of hospitalization for
HF (NYHA functional Class II– IV), with HF as the primary diagnosis.
The diagnosis was based on a combination of typical signs and symp-
toms according to the European Society of Cardiology guidelines1
for which a hospital stay was considered necessary, and the need for
intravenously administered medication. During hospitalization, all
patients received standard care, both pharmacological, and non-
pharmacological, according to the guidelines1 in a cardiology ward,
staffed by cardiologists and registered nurses. Patients were 18 years
or older and had evidence of structural underlying heart disease as
shown at cardiovascular imaging. Exclusion criteria were: concurrent
inclusion in a study requiring additional visits to research health care
personnel; restrictions that made the patient unable to fill in data col-
lection forms; invasive intervention within the last 6 months or planned
during the following 3 months; or ongoing evaluation for heart trans-
plantation. All patients gave written informed consent. Although all
patients in the COACH study had HF as the primary diagnosis and
were included in experienced HF centres, in the current analyses we
only included patients who had a BNP plasma level .100 pg/mL, to
strengthen the evidence for a diagnosis of HF in all patients.1,19.
The study was performed in accordance with the principles outlined
in the Declaration of Helsinki and was approved by the Medical Ethics
Committee in each participating centre.
Data collection
Left ventricular ejection fraction and brain natriuretic
peptide
Data on left ventricular function (LV function) were obtained by stan-
dard trans-thoracic echocardiography. These data were used to
distinguish between HF-PEF and HF-REF. Reduced LV systolic function
was defined as a LV ejection fraction (LVEF) ,40% (HF-REF); and pre-
served LV systolic function was defined as an LVEF ≥40% (HF-PEF). In
the current analyses, only patients with complete echocardiographic
data were included. Plasma BNP levels were determined within 4 h
of blood collection (1 mL blood, collected in EDTA), on the day of
hospital discharge or on the day before hospital discharge. All BNP
measurements were performed using a fluorescence immunoassay
kit (Triagew; Biosite Incorporated, San Diego, CA, USA).19.
Quality of life
Data on QoL in the COACH study were collected during the index
hospitalization and during follow-up. To minimize the confounding
effect of the recent hospitalization on QoL, we used QoL data collected
1 month after discharge. Quality of life was assessed in three different
ways: global well-being, general QoL, and disease-specific QoL.
Global well-being was assessed by Cantril’s Ladder of Life. This is a
single-item measure which asks the patient to rate their sense of well-
being on a ladder, with 10 reflecting the best possible life imaginable
and 0 reflecting the worst possible life imaginable. A higher score
indicates better well-being.20.
General QoL was assessed by the Medical Outcome Study 36-item
General Health Survey (RAND-36), a self-report questionnaire of
general health status. It is a well-validated generic, 36-item question-
naire that includes nine health concepts that represent dimensions of
QoL: physical functioning, social functioning, role limitations because
of physical functioning, role limitations because of emotional function-
ing, mental health, vitality, bodily pain, general health, and perceived
health change. Each dimension has a score between 0 and 100; a
higher score means better health.21.
Disease-specific QoL was measured by means of the Minnesota
Living with Heart Failure (MLwHF) questionnaire.22 The MLwHF ques-
tionnaire is a 21-item questionnaire assessing how HF has affected the
life of the respondent during the last month. The MLwHF has a scoring
range of 0 for no impairment as a result of HF to 105 for maximum
impairment. The questions cover symptoms and signs relevant to
HF, physical activity, social interaction, sexual activity, work, and
emotions. Three scores can be determined: an overall score
(21 items, 0–105), the physical dimension (8 items, 0–40), and the
emotional dimension (5 items, 0–25). Higher MLwHF scores mean a
worse QoL.
Statistical analysis
The two patient groups (HF-PEF and HF-REF) were matched by age
(10 year categories) and gender to have a fair test of differences.23
First, descriptive statistics were used to characterize the HF-PEF and
HF-REF patients. For continuous variables means and standard devi-
ations and for categorical variables frequencies with percentages
were used. Secondly, differences in QoL between both HF patient
groups were tested univariately using the Mann–Whitney U test.
Thirdly, a Spearman correlation was calculated between BNP and
QoL in the total group to analyse the relation between QoL and
BNP levels. Finally, to adjust for an objective measure of the severity
of HF, an analysis of covariance was performed using QoL scores as
the dependent variable and BNP as the covariate. The more subjective
measure for the severity of HF, NYHA functional class, was not
included in the analysis because of an overlap with (physical
dimensions of) QoL.
Analyses were performed using SPSS for windows version 16 (SPSS
Inc., Chicago, IL, USA). Outcomes were considered statistically
significant when P, 0.05.
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Of the 1023 patients included in the main COACH study, an LVEF
measurement and a BNP level were available in 698 patients. Of
these, 627 patients had a BNP level .100 pg/mL. Within this
patient sample, QoL questionnaires at 1 month after discharge
were completed by 485 patients. Only patients who completed
all questionnaires were included in the current study. Of these,
31% had an LVEF ≥40 and 69% had an LVEF ,40%.
After matching for age and gender, both patient groups consisted
of 145 patients. Due to the process of matching, 195 HF patients (190
LVEF,40%, 5 LVEF ≥40%) were not analysed. These excluded HF
patients who were younger, more often male, had a lower mean
LVEF, and their QoL was slightly better on physical functioning of
the MLwHF questionnaire. (P, 0.05). All other domains of QoL,
and the BNP levels were similar in both groups.
Characteristics
Patients with HF-PEF were on average 72 (+10) years old, 41%
were female, and the mean LVEF was 50% (+8%). Patients with
HF-REF were on average 72 (+10) years old, 41% were female,
and the mean LVEF was 26% (+7%) (Table 1). In patients with
HF-PEF the prevalence of hypertension was higher than in patients
with HF-REF (P ¼ 0.025). Brain natriuretic peptide levels were
significantly higher in the HF-REF patient group (P ¼ 0.001). More
patients with HF-REF were classified as NYHA functional Class
III–IV at discharge than patients with HF-PEF (P, 0.001) (Table 1).
Quality of life
Global well-being, as measured with Cantril’s Ladder of Life, did
not differ significantly between patients with HF-PEF and HF-REF
(6.3 vs. 6.3, P ¼ 0.862).
Scores of all dimensions of the RAND-36 varied between 17
and 78, on the theoretical range between 0 and 100, with the
lowest scores for role limitations physical, physical functioning,
and health change. None of the dimensions of the general QoL,
measured with RAND-36, differ significantly between HP-REF
and HF-REF patients, except for bodily pain (HF-PEF vs. HF-REF,
70 vs. 78, P ¼ 0.006).
The mean score on the total scale of the MLwHF was 41. On the
physical and emotional subscales, mean scores were 21 and 8,
respectively. Also on the MLwHF questionnaire, patients with
HF-PEF did not rate their QoL different than patients with
HF-REF. The total scores as well as the scores on the physical and
emotional functioning subscales did not differ significantly between
both groups (Table 2).
Relationship between brain natriuretic
peptide and quality of life
Global well-being was not significantly related to BNP levels in the
total patient group (n ¼ 290). Of the dimensions of the RAND-36,
health change was significantly correlated to BNP levels (r ¼
0.124, P, 0.05). All other dimensions of the RAND-36 were
not significantly correlated to BNP levels. Disease-specific QoL,
as measured by means of the MLwHF questionnaire, was signifi-
cantly correlated with BNP levels. There was a correlation with
the total score (r ¼ 0.132, P, 0.05) and the physical subscale of
the MLwHF questionnaire (r ¼ 0.151, P, 0.01). There was no sig-
nificant correlation between BNP levels and the emotional sub-
scale of the MLwHF questionnaire.
Adjustment for brain natriuretic peptide
After adjusting the QoL scores for BNP level, QoL was not associ-
ated with LVEF. There were no differences in the adjusted global
well-being scores between patients with HF-PEF and HF-REF (6.3
vs. 6.3, P ¼ 0.671) (Figure 1). The adjusted general QoL did not
differ between the two groups, except for the bodily pain dimen-
sion, in which patients with HF-PEF had a significantly lower score,
which means worse QoL (70 vs. 77, P ¼ 0.020) (Figure 1) com-
pared with the HF-REF. The scores on the disease-specific QoL
questionnaire (MLwHF) did not differ on the total score or on
both subscales (physical and emotional functioning) between the
two groups (Figure 1).
Discussion
The main finding of the present study is that QoL in patients with
HF-PEF is as severely affected as it is in patients with HF-REF. This
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 1 Demographic and clinical characteristics of
the matched patient groups at discharge
HF-REF HF-PEF P-value
(n5 145) (n 5 145)
Demographics
Age (years) 72+10 72+10 0.739
Female 41% 41% 1.000
Clinical characteristics
LVEF% 26+7 50+8 ,0.001
NYHA III– IV 61% 38% ,0.001
BNP (pg/mL) median
(IQR)
516 (290–1125) 370 (215–755) 0.001
Hypertension 37% 50% 0.025
Ischaemic heart failure 43% 43% 0.946





ACE-inhibitors/ARB 88% 81% 0.102
Beta-blockers 67% 66% 0.901
Diuretics 97% 97% 1.000
Comorbidities
COPD 22% 30% 0.109
Diabetes 30% 28% 0.699
Stroke 10% 7% 0.394
LVEF, left ventricular ejection fraction; NYHA, New York Heart Association; BNP,
B-type natriuretic peptide; IQR, inter-quartile range; ACE, angiotensin-converting
enzyme; ARB, angiotensin receptor blocker; COPD, chronic obstructive
pulmonary disease
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similarity between HF-PEF and HF-REF patients is consistent on
several domains of QoL, both disease generic and disease specific.
When we adjusted the QoL scores for BNP, as a marker for the
severity of the disease, an association between QoL and LVEF
was not found, despite the significant correlation between BNP
and several QoL domains (health change of the RAND-36, physical
and total scores of the MLwHF questionnaire), i.e. patients with
HF-PEF and HF-REF with similar BNP levels, had the same impair-
ment in QoL.
Although the two patient groups differed significantly in terms of
the number of patients in NYHA III– IV at discharge, and a linear
association between NYHA and (physical) QoL could be
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
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Table 2 Quality of life in heart failure patients with reduced ejection fraction and heart failure patients with preserved
ejection fraction
Total HF-REF HF-PEF P-valuea
(n5 290) (n 5 145) (n5 145)
Baseline 1 month Baseline 1 month Baseline 1 month
Ladder of Life
Well-being 6.3+2 6.3+2 6.5+2 6.3+2 6.2+2 6.3+1 0.866
RAND-36
Physical functioning 34+27 40+28 32+27 38+27 35+27 43+28 0.165
Social functioning 53+32 57+29 51+33 55+31 55+31 59+27 0.296
Role limitations physical 18+33 20+34 19+33 17+33 17+33 22+35 0.156
Role limitations emotional 51+45 48+46 53+46 48+46 50+46 49+46 0.807
Mental health 67+23 70+21 67+24 69+21 66+21 70+20 0.908
Vitality 41+23 49+23 42+25 48+23 39+22 49+23 0.938
Bodily pain 63+33 74+28 66+32 78+26 61+33 70+28 0.006
General health 44+18 45+19 44+17 45+19 44+19 45+19 0.956
Health change 26+23 34+29 25+23 34+29 27+23 34+29 0.817
Minnesota Living with Heart Failure
Total 45+21 41+22 46+21 41+23 44+21 41+21 0.816
Physical functioning 24+10 21+11 25+10 21+11 24+11 20+11 0.704
Emotional functioning 7+6 8+6 7+6 8+6 7+6 8+6 0.692
aComparison between HF-REF and HF-PEF patient groups at 1 month after discharge.
Figure 1 Quality of life in patients with HF-REF (LVEF ,40%) and HF-PEF (LVEF ≥40%), multivariate tested and adjusted for brain natriuretic
peptide. *P, 0.05. HF-REF, heart failure patients with reduced ejection fraction; HF-PEF, heart failure patients with preserved ejection fraction HF
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suggested, we did not find significant differences in QoL scores.
This might be due to the fact that QoL includes more dimensions
than physical function alone as measured by NYHA functional
class. Although NYHA functional class definitely influences QoL,
e.g. the scores between both groups differed the most for the
physical function dimensions, the QoL scores between the two
groups did not differ significantly.
It is well known that QoL is affected by gender and age and
patients with HF-PEF and HF-REF are different regarding these
two variables. Patients with HF-PEF are more often female and
older9,10 and in general it would seem that QoL is lower in patients
with HF-PEF. By using the matching technique (on age and
gender23) we showed, however, that possible differences in QoL
are not due to differences in LVEF but probably caused by the
presence of more patients with higher age and female sex in the
HF-PEF group compared with the HF-REF group.
To our knowledge this is the first study to compare QoL
between HF-PEF and HF-REF patients, which has used an indepen-
dent and reliable marker for the severity of HF (i.e. BNP). Although
the diagnosis of HF in the COACH study was already well defined,
in the current study we only included patients with plasma BNP
levels .100 pg/mL. In previous studies, HF patients were defined
using more subjective criteria such as NYHA class or an admission
to the hospital with a cardiovascular problem in the previous 6
months,13 an admission to the cardiology ward with symptoms
of HF,11 the application of the European Study Group criteria12,
or a clinical score of three or greater from NHANES I (National
Health and Nutrition Examination Survey I).14,15 There
are several possible subjective and objective markers of disease
severity in HF, for example, NYHA functional class, sodium restric-
tion, and renal dysfunction. We chose to use BNP levels as a
marker of disease severity in our analysis, because this is an objec-
tive and a generally accepted measure for the severity of HF,1 and
has no direct overlap with (physical dimensions of) QoL like
NYHA functional class.
There are almost no studies published on the comparison of
QoL between HF-PEF and HF-REF. One of the few studies that
have been published is by Lewis et al.13 from the large CHARM
population (n ¼ 2709), who reported that QoL was associated
with LVEF and was equally impaired in HF-PEF and HF-REF. Our
results further extend the findings of this previous study in
several aspects. First, our study had the advantage of using an
objective marker for the presence of HF (LVEF combined with
elevated BNP levels in both the HF-PEF and HF-REF groups),
making us more confident that the patients with HF-PEF had HF
and were not suffering from different diagnoses. Secondly, our
study extends previous observations by using multiple QoL assess-
ments to demonstrate the similarity in different domains of QoL,
such as general well-being, physical and social functioning, role
limitations, and disease-specific QoL between the two groups.
Thirdly, we deliberately chose to match the two patient groups
instead of putting age and gender into the multivariate model to
have a fair test of comparison. In QoL research between groups
of patients, statistical analyses often ignore the meaning of differ-
ences in age and gender. When age and gender are treated as nui-
sance variables and are dealt with by statistical control, we are
actually forming a counterfactual situation. In this sense ‘controlling
for age and gender’ substantively means attempting to eliminate
the effects of significant differences in role responsibilities.23
Quality of life is experienced differently by men and women, and
by younger and older patients, and therefore we decided to
match the two patient groups instead of controlling for age.
While patients with HF-PEF appear to have similar symptoms of
HF and their prognosis is as poor as those with HF-REF9,10,24, no
treatment option has been proven effective in this population.
Although favourable effects on clinical endpoints (hospitalizations
and mortality) have been suggested in some (sub-) populations
of patients with HF-PEF for angiotensin-converting enzyme inhibi-
tors,25 angiotensin receptor blockers,26 and beta-blockers,27 none
of these agents has shown a significant benefit on outcome in large
randomized studies, and none of them has therefore received a
recommendation in current guidelines.1 When it comes to QoL,
few studies have focused specifically on the HF-PEF population.
Nevertheless, it appears that QoL is gaining increasing attention
in HF-PEF, and in one recently reported study with valsartan28
and in another ongoing study with spironolactone,29 QoL is one
of the important endpoints.
There are a few limitations to the present study. First, due to the
process of matching 195 patients, mostly patients with HF-REF,
were excluded from the analysis. However, we deliberately
chose to match the two patient groups instead of including age
and gender in the multivariate analysis to have a fair test of com-
parison, and gain a more representative clinical insight in the com-
parison of QoL between patients with HF-PEF and HF-REF.23
Secondly, we defined HF-PEF as an LVEF ≥40%. At present, the
cut-off point of LVEF to diagnose HF-REF or HF-PEF is still a
matter of debate, we chose a cut-off of 40% because it has been
used in other large databases,13 and because otherwise very few
patients would have been included in the HF-PEF group. Thirdly,
in the current study we used QoL data at 1 month after discharge,
while BNP levels were collected at discharge. We deliberately
chose to use the QoL data at 1 month after discharge to minimize
the confounding effect of the recent hospitalization.
In conclusion, patients with symptomatic HF with preserved
LVEF (HF-PEF) and elevated levels of BNP suffer from their HF
as much as age- and gender-matched HF patients with HF-REF,
resulting in a comparably low QoL and well-being. Pharmacological
and non-pharmacological management interventions that have
proved to be successful in HF-REF patients to improve QoL
might also be successful in HF-PEF too. Further research to test
whether these interventions can improve QoL is now needed.
Funding
The COACH study was supported by a programme grant from the
Netherlands Heart Foundation (grant 2000Z003). V.V. is a Clinical
Established Investigator of the Netherlands Heart Foundation
(grant D97.017).
Additional unrestricted grants were obtained from Biosite Europe,
France, Roche Diagnostics, The Netherlands and Novartis Pharma
BV, The Netherlands.
Conflict of interest: V.V. has received board membership fees from
Amgen and Pfizer and consulting fees from Medtronic, Biotronic, Alere
and Vifor.
QoL is impaired similarly in HF patients with PEF and REF Page 5 of 6
 at R









1. Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P,
Poole-Wilson PA, Stro¨mberg A, van Veldhuisen DJ, Atar D, Hoes AW,
Keren A, Mebazaa A, Nieminen M, Priori SG, Swedberg K. ESC Guidelines for
the diagnosis and treatment of acute and chronic heart failure 2008: the Task
Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure
2008 of the European Society of Cardiology. Eur J Heart Fail 2008;10:933–989.
2. Lesman-Leegte I, van Veldhuisen DJ, Hillege HL, Moser D, Sanderman R,
Jaarsma T. Depressive symptoms and outcomes in patients with heart failure:
data from the COACH study. Eur J Heart Fail 2009;11:1202–1207.
3. Lesman-Leegte I, Jaarsma T, Coyne JC, Hillege HL, Van Veldhuisen DJ,
Sanderman R. Quality of life and depressive symptoms in the elderly: a compari-
son between patients with heart failure and age- and gender-matched community
controls. J Card Fail 2009;15:17–23.
4. Juenger J, Schellberg D, Kraemer S, Haunstetter A, Zugck C, Herzog W, Haass M.
Health related quality of life in patients with congestive heart failure: comparison
with other chronic diseases and relation to functional variables. Heart 2002;87:
235–241.
5. Stevenson LW. Design of therapy for advanced hear failure. Eur J Heart Fail 2005;
7:323–331.
6. Jaarsma T, Beattie JM, Ryder M, Rutten FH, McDonagh T, Mohacsi P, Murray SA,
Grodzicki T, Bergh I, Metra M, Ekman I, Angermann C, Leventhal M, Pitsis A,
Anker SD, Gavazzi A, Ponikowski P, Dickstein K, Delacretaz E, Blue L,
Strasser F, McMurray J, Advanced heart Failure S2006tudy Group of the HFA
of the ESC. Palliative care in heart failure: a position statement from the palliative
care workshop of the Heart Failure Association of the European Society of Car-
diology. Eur J Heart Fail 2009;11:433–443.
7. Iqbal J, Francis L, Reid J, Murray S, Denvir M. Quality of life in patients with chronic
heart failure and their carers: a 3-year follow-up study assessing hospitalization
and mortality. Eur J Heart Fail 2010;12:1002–1008.
8. Zuluaga MC, Guallar-Castillo´n P, Lo´pez-Garcı´a E, Banegas JR, Conde-Herrera M,
Olcoz-Chiva M, Rodrı´guez-Pascual C, Rodriguez-Artalejo F. Generic and disease-
specific quality of life as a predictor of long-term mortality in heart failure. Eur J
Heart Fail 2010;12:1372–1378.
9. Paulus WJ, van Ballegoij JJ. Treatment of heart failure with normal ejection frac-
tion: an inconvenient truth!. J Am Coll Cardiol 2010;55:526–537.
10. Kindermann M, Reil JC, Pieske B, van Veldhuisen DJ, Bo¨hm M. Heart failure with
normal left ventricular ejection fraction: what is the evidence? Trends Cardiovasc
Med 2008;18:280–292.
11. Jaarsma T, Halfens R, Abu-Saad HH, Dracup K, Stappers J, van Ree J. Quality of life
in older patients with systolic and diastolic heart failure. Eur J Heart Fail 1999;1:
151–160.
12. O’Mahony MS, Sim MF, Ho SF, Steward JA, Buchalter M, Burr M. Diastolic heart
failure in older people. Age Ageing 2003;32:519–524.
13. Lewis EF, Lamas GA, O’Meara E, Granger CB, Dunlap ME, McKelvie RS,
Probstfield JL, Young JB, Michelson EL, Halling K, Carlsson J, Olofsson B,
McMurray JJ, Yusuf S, Swedberg K, Pfeffer MA, CHARM Investigators. Character-
ization of health-related quality of life in heart failure patients with preserved
versus low ejection fraction in CHARM. Eur J Heart Fail 2007;9:83–91.
14. Austin BA, Wang Y, Smith GL, Vaccarine V, Krumholz HM, McNamara RL. Systo-
lic function as a predictor of mortality and quality of life in long-term survivors
with heart failure. Clin Cardiol 2008;31:119–124.
15. Kitzman DW, Little WC, Brubaker PH, Anderson RT, Hundley WG,
Marburger CT, Brosnihan B, Morgan TM, Steward KP. Pathophysiological charac-
terization of isolated diastolic heart failure in comparison to systolic heart failure.
JAMA 2002;288:2144–2150.
16. Maisel A, Mueller C, Adams K Jr, Anker SD, Aspromonte N, Cleland JG,
Cohen-Solal A, Dahlstrom U, DeMaria A, Di Somma S, Fillippatos GS,
Fonarow GC, Jourdain P, Komajda M, Liu PP, McDonagh T, McDonald K,
Mebazaa A, Nieminen MS, Peacock WF, Tubaro M, Valle R, Vanderhyden M,
Yancy CW, Zannad F, Braunwald E. State of the art: using natriuretic peptide
levels in clinical practice. Eur J Heart Fail 2008;10:824–839.
17. Jaarsma T, Van Der Wal MH, Hogenhuis J, Lesman I, Luttik ML, Veeger NJ, Van
Veldhuisen DJ. Design and methodology of the COACH study: a multicenter ran-
domised Coordinating study evaluating Outcomes of Advising and Counselling in
Heart failure. Eur J Heart Fail 2004;6:227–233.
18. Jaarsma T, van der Wal MH, Lesman-Leegte I, Luttik ML, Hogenhuis J, Veeger NJ,
Sanderman R, Hoes AW, van Gilst WH, Lok DJ, Dunselman PH, Tijssen JG,
Hillege HL, van Veldhuisen , Coordinating Study Evaluating Outcomes of Advising
and Counseling in Heart Failure (COACH) Investigaters. Effect of moderate or
intensive disease management program on outcome in patients with heart
failure: Coordinating Study Evaluating Outcomes of Advising and Counseling in
Heart Failure (COACH). Arch Intern Med 2008;168:316–324.
19. Hogenhuis J, Voors AA, Jaarsma T, Hillege HL, Hoes AW, van Veldhuisen DJ. Low
prevalence of B-type natriuretic peptide levels ,100 pg/mL in patients with heart
failure at hospital discharge. Am Heart J 2006;151:1012e1–1012e5.
20. Cantril H. The Pattern of Human Concerns. New Brunswick, NJ: Rutgers University
Press; 1965.
21. Van der Zee KI, Sanderman R, Heyink JW, de Haes H. Psychometric qualities of
the RAND 36-item Health Survey 1.0: a multidimensional measure of general
health status. Int J Behav Med 1996;3:104–122.
22. Rector TS, Kubo SH, Cohn JN. Patients’ self-assessment of their congestive heart
failure: content, reliability and validity of a new measure, the Minnesota Living with
Heart Failure questionnaire. Heart Fail 1987;3:198–209.
23. Sanderman R, Coyne JC, Ranchor AV. Age: nuisance variable to be eliminated
with statistical control or important concern? Patient Educ Couns 2006;61:
315–316.
24. Lenzen MJ, Scholte op Reimer WJ, Boersma E, Vantrimpont PJ, Follath F,
Swedberg K, Cleland J, Komajda M. Differences between patients with a pre-
served and a depressed left ventricular function: a report from the EuroHeart
Failure Survey. Eur Heart J 2004;25:1214–1220.
25. Cleland JG, Tendera M, Adamus J, Freemantle N, Plonski L, Taylor J. The perindo-
pril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J 2006;
27:2338–2345.
26. Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL,
Olofsson B, Ostergren J, CHARM Investigators and Committees. Effects of can-
desartan in patients with chronic heart failure and preserved left-ventricular ejec-
tion fraction: the CHARM-Preserved Trial. Lancet 2003;362:777–781.
27. van Veldhuisen DJ, Cohen-Solal A, Bo¨hm M, Ankder SD, Babalis D, Roughton M,
Coats AJ, Poole-Wilson PA, Flather MD, SENIORS Investigators. Beta-blockade
with nebivolol in elderly heart failure patients with impaired and preserved left
ventricular ejection fraction: Data from SENIORS (Study of Effects of Nebivolol
Intervention on Outcomes and Rehospitalization in Seniors with Heart Failure).
J Am Coll Cardiol 2009;53:2150–2158.
28. Parthasarathy HK, Pieske B, Weisskopf M, Andrews CD, Brunel P, Struthers AD,
MacDonald TM. A randomized, double-blind, placebo-controlled study to
determine the effects of valsartan on exercise time in patients with symptomatic
heart failure with preserved ejection fraction. Eur J Heart Fail 2009;11:
980–989.
29. Edelmann F, Schmidt AG, Gelbrich G, Binder L, Herrmann-Lingen C, Halle M,
Hasenfuss G, Wachter R, Pieske B. Rationale and design of the ‘aldosterone
receptor blockade in diastolic heart failure’ trial: a double-blind, randomized,
placebo-controlled, parallel group study to determine the effects of spironolac-
tone on exercise capacity and diastolic function in patients with symptomatic dias-
tolic heart failure (Aldo-DHF). Eur J Heart Fail 2010;12:874–882.
T. Hoekstra et al.Page 6 of 6
 at R
ijksuniversiteit Groningen on June 29, 2011
e
u
rjhf.oxfordjournals.org
D
ow
nloaded from
 
